IP1: THE UK NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE): NEW DEVELOPMENTS
THE ERG PERSPECTIVE
Matt D Stevenson PhD
Technical Director, School for Health and Related Research Technology Assessment (ScHARR – TAG), University of Sheffield, Sheffield, UK
RECOMMENDATIONS FOR RESEARCH PLANNING
Sorrel E Wolowacz PhD
Senior Health Economist, RTI Health Solutions, Manchester, UK
IP2: PHARMACEUTICAL POLICIES IN EUROPEAN COUNTRIES: AIMING AT COST CONTAINMENT, COST-EFFECTIVENESS OR EQUITY?
PHARMACEUTICAL POLICIES IN EUROPEAN COUNTRIES: THE NETHERLANDS
Marc Koopmanschap PhD
Researcher, Institute for Medical Technology Assessment, Erasmus MC, Rotterdam, The Netherlands
Pharmaceutical Policies in European Countries: Recent Experiences in England
John Hutton PhD
Professor of Health Economics, Department of Health Sciences – Health Economics, University of York, York, UK
IP3: THE DEVIL IS IN THE DETAILS: INTERNATIONAL COMPARISON OF TECHNOLOGY ASSESSMENT PROCESSES AND PAYER UPTAKE OF PERSONALIZED MEDICINE AND IMPLICATIONS FOR THE FIELD
THE DEVIL IS IN THE DETAILS: INTERNATIONAL COMPARISON OF TECHNOLOGY ASSESSMENT PROCESSES AND PAYER UPTAKE OF PERSONALIZED MEDICINE AND IMPLICATIONS FOR THE FIELD
Eric C Faulkner MPH, Senior Director, Pricing & Reimbursement, RTI Health Solutions, Research Triangle Park, NC, USA; Lieven Annemans PhD, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; Uwe Siebert MD, MPH, MSc, Professor, UMIT – University for Health Sciences, Medical Informatics and Technology, Hall i.T, Austria; Katherine Payne PhD, Senior Research Fellow, University of Manchester, Manchester, UK
IP4: WHAT SHOULD BE THE ROLE OF PATIENT PREFERENCES IN MAKING HEALTHCARE RESOURCE ALLOCATION DECISIONS?
WHAT SHOULD BE THE ROLE OF PATIENT PREFERENCES IN MAKING HEALTHCARE RESOURCE ALLOCATION DECISIONS?
Mark J Sculpher PhD
Professor of Health Economics, Centre for Health Economics, University of York, York, UK
Using Preferences in Decision Making
Deborah A. Marshall PhD
Associate Professor, Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada
IP5: PATIENT-REPORTED OUTCOMES AS A STANDARD APPROACH FOR HEALTH CARE POLICY MAKERS
IMPLEMENTATION OF PROS IN COOPERATIVE GROUPS
Carolyn Gotay PhD
Professor, University of British Columbia, Vancouver, BC, Canada
PATIENT REPORTED OUTCOMES (PROS) IN A CLINICAL TRIAL SETTING: IMPLICATIONS AND CHALLENGES
Chantal Quinten MSc
Researcher, Quality of Life Department, EORTC, Brussels, Belgium
IP6: SOCIETAL VERSUS PAYER PERSPECTIVES FOR COST-EFFECTIVENESS ANALYSIS: CAN WE JUSTIFY VARIATION BETWEEN DECISION MAKERS?
ARGUMENTS FOR A SOCIAL PERSPECTIVE
Bengt Jonsson PhD
Professor, Department of Economics, Stockholm School of Economics, Stockholm, Sweden
IP8: IQWIG AND THE EFFICIENCY FRONTIER – HOW CAN WE MEASURE PATIENT RELEVANT OUTCOMES?
IQWIG AND THE EFFICIENCY FRONTIER – HOW CAN WE MEASURE PATIENT RELEVANT OUTCOMES?
Olaf Pirk PhD, MD
Principal, Health Economics & Outcomes Research, IMS Health, Nuremberg, Germany
IP9: HOW SHOULD HTA METHODS BE ADAPTED TO MEET THE RISING EXPECTATIONS OF DECISION MAKERS FOR MEDICAL DEVICES AND DIAGNOSTICS REIMBURSEMENT?
HOW SHOULD HTA METHODS BE ADAPTED TO MEET THE RISING EXPECTATIONS OF DECISION MAKERS FOR MEDICAL DEVICES AND DIAGNOSTICS REIMBURSEMENT?
Adrian Griffin MSc
VP Strategic Affairs, LifeScan EMEA, Buckinghamshire, UK
IP10: ESTIMATING THE COST-EFFECTIVENESS OF VACCINES – IS THE HEALTH ECONOMIST’S STANDARD TOOLBOX SUFFICIENTLY EQUIPPED?
ECONOMIC EVALUATION OF INFECTIOUS DISEASE PREVENTION
Philippe Beutels MSc, PhD
Professor, Centre for Health Economics Research and Modeling Infectious Diseases (CHERMID), Centre for the Evaluation of Vaccines (CEV), University of Antwerp, Antwerp, Belgium
Economic Evaluation of Infectious Disease Prevention
Matthew Taylor PhD
Senior Consultant, York Health Economics Consortium, University of York, York, UK |
